Information Provided By:
Fly News Breaks for May 20, 2016
TNXP
May 20, 2016 | 07:43 EDT
Oppenheimer analyst Carlos Solorzano believes the weakness in Tonix Pharmaceuticals' shares is unwarranted and says he is encouraged by the broad, positive effects of its TNX-102 on Post traumatic stress disorder, or PTSD. The analyst reiterates an Outperform rating on the stock and raised his price target on the shares to $13 from $10 following what he views as a "significant de-risking" of the PTSD program.
News For TNXP From the Last 2 Days
There are no results for your query TNXP
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.